ITFI20080035A1 - DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA - Google Patents
DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA Download PDFInfo
- Publication number
- ITFI20080035A1 ITFI20080035A1 IT000035A ITFI20080035A ITFI20080035A1 IT FI20080035 A1 ITFI20080035 A1 IT FI20080035A1 IT 000035 A IT000035 A IT 000035A IT FI20080035 A ITFI20080035 A IT FI20080035A IT FI20080035 A1 ITFI20080035 A1 IT FI20080035A1
- Authority
- IT
- Italy
- Prior art keywords
- composition according
- disinfectant
- composition
- myrrh
- zinc
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 38
- 210000002200 mouth mucosa Anatomy 0.000 title claims description 24
- 238000011282 treatment Methods 0.000 title claims description 16
- 230000002265 prevention Effects 0.000 title claims description 14
- 208000003265 stomatitis Diseases 0.000 title claims description 9
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical group [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 32
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 31
- 239000000645 desinfectant Substances 0.000 claims description 23
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 18
- 229960003720 enoxolone Drugs 0.000 claims description 18
- 239000011592 zinc chloride Substances 0.000 claims description 16
- 235000005074 zinc chloride Nutrition 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 15
- 239000002324 mouth wash Substances 0.000 claims description 14
- 150000003751 zinc Chemical class 0.000 claims description 13
- 235000006965 Commiphora myrrha Nutrition 0.000 claims description 11
- 235000007265 Myrrhis odorata Nutrition 0.000 claims description 11
- 239000000307 commiphora myrrha gum Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 206010042129 Stomatitis and ulceration Diseases 0.000 claims description 10
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical group CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 208000025865 Ulcer Diseases 0.000 claims description 9
- 239000001046 green dye Substances 0.000 claims description 9
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 9
- 239000008368 mint flavor Substances 0.000 claims description 9
- 239000007968 orange flavor Substances 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 8
- 229940051866 mouthwash Drugs 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 239000000606 toothpaste Substances 0.000 claims description 8
- 229940034610 toothpaste Drugs 0.000 claims description 8
- 125000002091 cationic group Chemical group 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 6
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002216 methylparaben Drugs 0.000 claims description 6
- 230000003232 mucoadhesive effect Effects 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- 229940042129 topical gel Drugs 0.000 claims description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 230000001680 brushing effect Effects 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 230000000306 recurrent effect Effects 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 240000007311 Commiphora myrrha Species 0.000 claims description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 4
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 208000002399 aphthous stomatitis Diseases 0.000 claims description 3
- 208000020670 canker sore Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 229960004667 ethyl cellulose Drugs 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 229910002055 micronized silica Inorganic materials 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229960004291 sucralfate Drugs 0.000 claims description 3
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 230000003144 traumatizing effect Effects 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 2
- 229960001950 benzethonium chloride Drugs 0.000 claims description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960002798 cetrimide Drugs 0.000 claims description 2
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 239000004246 zinc acetate Substances 0.000 claims description 2
- 235000013904 zinc acetate Nutrition 0.000 claims description 2
- 239000011746 zinc citrate Substances 0.000 claims description 2
- 235000006076 zinc citrate Nutrition 0.000 claims description 2
- 229940068475 zinc citrate Drugs 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 239000011686 zinc sulphate Substances 0.000 claims description 2
- 235000009529 zinc sulphate Nutrition 0.000 claims description 2
- 238000009412 basement excavation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 description 10
- 240000009023 Myrrhis odorata Species 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 229940117958 vinyl acetate Drugs 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- 235000013734 beta-carotene Nutrition 0.000 description 2
- 239000011648 beta-carotene Substances 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000178435 Eliokarmos dubius Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960001391 alfentanil Drugs 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000002455 dental arch Anatomy 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- YKQOSKADJPQZHB-YNWHQGOSSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1s)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Polymers CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O YKQOSKADJPQZHB-YNWHQGOSSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- -1 oxipentifylline Chemical compound 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 231100000901 systemic toxic effect Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940072358 xylocaine Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Descrizione dell 'Invenzione Industriale dal titolo; Description of the Industrial Invention entitled;
“COMPOSIZIONE AD USO ODONTOIATRICO PER LA PREVENZIONE ED IL TRATTAMENTO DELLA STOMATITE E DELLE ULCERAZIONI DELLA MUCOSA ORALE” "COMPOSITION FOR DENTAL USE FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERATIONS OF THE ORAL MUCOSA"
DESCRIZIONE DESCRIPTION
Ambito dell' invenzione: Scope of the invention:
La presente invenzione riguarda il settore odontoiatrico e più precisamente si riferisce ad una composizione per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale. Tale composizione può essere utilizzata, come un collutorio, come un gel topico o come un dentifricio. The present invention relates to the dental sector and more precisely refers to a composition for the prevention and treatment of stomatitis and ulcerations of the oral mucosa. Such a composition can be used, as a mouthwash, as a topical gel or as a toothpaste.
Breve descrizione della tecnica nota Brief description of the prior art
La mucosite orale, chiamata anche stomatite, è una complicanza comune e debilitante della chemioterapia e radioterapia, con una incidenza del 40% circa dei pazienti. Questa è il risultato degli effetti tossici sistemici degli agenti chemoterapici e degli effetti locali della terapia radiante sulla mucosa orale. La mucosite orale è una fiogosi della mucosa orale che può variare da un semplice rossore a ulcerazioni gravi. I sintomi della mucosite variano dal dolore ad un disagio o inabilità nei Lollerare cibi o fluidi. La mucosite può essere così severa da dover procastinare il trattamento chemioterapico, limitando cosi l'efficacia della terapia antitumorale. Tali pazienti con mucosa e come conseguenza chemioterapia e radioterapia sono predisposti ad infezioni opportunistiche della bocca. Ε' perciò estremamente importante prevenire la mucosite quando è possibile, o trattarla per ridurre la sua severità e le possibili complicazioni. Molti trattamenti sono stati utilizzati per prevenire o curare la mucosite orale: 1) interventi che riducono la tossicità dei farmaci chemioterapici a livello della mucosa orale includono collutori contenenti allopurinolo (specifico per terapia con 5-fluorouracile) oppure la crioterapia del cavo orale durante il bolo del 5-fluorouracile (che ha una breve emivita), riducendo così tramite la vasocostrizione la quota di antitumorale a livello della mucosa orale. 2) collutori con azione antiinfiammatoria e/o antibatterica (contenenti benzidamina, o corticosteroidi, o camomilla). 3) anestetici topici come soluzioni viscose contenenti xylocaina o lidocaina ecc. 4) collutori contenenti antisettici (clorexidina, iodio povidone, perossido di idrogeno). 5) collutori o compresse orosolubili contenenti agenti antibatterici, antifungini, antivirali (nistatina, clotrimazolo, acyclovir, PTA compresse (polimixina E tobramicina anfotericina B)). 6) sostanze filmogene protettive di barriera della mucosa orale (soluzioni contenenti sucralfato, alginato di sodio, kaolino-pectina). 7) sostanze citoprotettive (beta-carotene (provitamina A), vitamina E, oxipentifillina, azelastina, prostaglandine E1 e E2 utilizzati localmente. 8) stimolanti le cellule della mucosa orale (applicazioni di laser a bassa energia, glutamina. 9) sostanze analgesiche quali oppioidi intravena (morfina), alfentanil, caramelle contenenti capsaicina. 10) psicoterapia, ipnosi, tecniche di rilassamento. Le ulcere della mucosa orale più frequentemente possono avere altre cause, in particolare ad es. possono essere conseguenti ad apparecchi dentali mal eseguiti o che si adattano scarsamente alle gengive, ad apparecchi ortodontici traumatizzanti per le mucose orali, allo spazzolamelo troppo energico e/o condotto con spazzolini con setole dure, per fratture di denti e/o otturazioni, morsi ai tessuti interni della bocca, bruciature da cibo, danni dovuti a procedure dentali aggressive, o come conseguenza di igiene orale professionale o sbiancamento professionale, traumi in genere. Oral mucositis, also called stomatitis, is a common and debilitating complication of chemotherapy and radiotherapy, with an incidence of approximately 40% of patients. This is the result of the systemic toxic effects of chemotherapeutic agents and the local effects of radiation therapy on the oral mucosa. Oral mucositis is a inflammation of the oral mucosa that can range from simple redness to severe ulceration. Symptoms of mucositis range from pain to discomfort or inability to tolerate food or fluids. Mucositis can be so severe that chemotherapy treatment has to be delayed, thus limiting the effectiveness of anticancer therapy. Such patients with mucosa and as a consequence chemotherapy and radiotherapy are predisposed to opportunistic infections of the mouth. It is therefore extremely important to prevent mucositis when possible, or to treat it to reduce its severity and possible complications. Many treatments have been used to prevent or treat oral mucositis: 1) interventions that reduce the toxicity of chemotherapy drugs in the oral mucosa include mouthwashes containing allopurinol (specific for therapy with 5-fluorouracil) or cryotherapy of the oral cavity during the bolus of 5-fluorouracil (which has a short half-life), thus reducing the amount of antitumor in the oral mucosa through vasoconstriction. 2) mouthwashes with anti-inflammatory and / or antibacterial action (containing benzydamine, or corticosteroids, or chamomile). 3) topical anesthetics such as viscous solutions containing xylocaine or lidocaine etc. 4) mouthwashes containing antiseptics (chlorhexidine, povidone iodine, hydrogen peroxide). 5) mouthwashes or buccal tablets containing antibacterial, antifungal, antiviral agents (nystatin, clotrimazole, acyclovir, PTA tablets (polymyxin E tobramycin amphotericin B)). 6) protective film-forming barrier substances of the oral mucosa (solutions containing sucralfate, sodium alginate, kaolin-pectin). 7) cytoprotective substances (beta-carotene (provitamin A), vitamin E, oxipentifylline, azelastine, prostaglandins E1 and E2 used locally. 8) stimulating the cells of the oral mucosa (applications of low-energy laser, glutamine. 9) analgesic substances such as intravenous opioids (morphine), alfentanil, sweets containing capsaicin. 10) psychotherapy, hypnosis, relaxation techniques. Oral mucosal ulcers more frequently can have other causes, in particular eg. may be the result of poorly executed dental appliances or which adapt poorly to the gums, traumatizing orthodontic appliances for the oral mucous membranes, brushing it too vigorously and / or conducted with brushes with hard bristles, for fractures of teeth and / or fillings, bites to internal tissues of the mouth, food burns, damage due to aggressive dental procedures, or as a result of professional oral hygiene or professional whitening, trauma in general.
Comunque esiste una condizione infiammatoria molto comune della mucosa orale definita come RAU (Recurrent Aphthous Ulcer) che interessa sia pure episodicamente il 25% della popolazione ed è caratterizzata da ulcere singole o multiple estremamente dolorose recidivanti, non contagiose. Può presentarsi in forma lieve o grave. La forma lieve è la più comune e costituisce circa l'80% di tutte le aftosi caratterizzata da ulcere singole o multiple estremamente dolorose recidivanti, non contagiose. L'incidenza maggiore si registra tra i 10 e 25 anni. Nel 50% dei casi è possibile riscontrare familiarità. Solitamente si presenta come singola ulcera ovale , dolente, con diametro inferiore a 10 mm, coperta da una membrana fibrinosa, circondata da un orletto eritematoso. Più rare sono le lesioni multiple. Le afre minori durano circa 10-14 giorni e guariscono spontaneamente senza lasciare cicatrici. Le recidive sono variabili da soggetto a soggetto, i periodi liberi da malattia variano da settimane ad anni. L'eziopatogenesi è complessa e del tutto non chiarita. Escluse patologie gravi (in cui l'aitosi orale è un sintomo) quali morbo celiaco, morbo di Crohn, colite ulcerosa, (naturalmente si devono escludere le lesioni neoplastiche della mucosa orale che si possono presentare come ulcere) ed esclusi eventuali deficit di ferro, folati e zinco, la stomatite afiosa può indicare una riduzione delle difese immunitarie, alterazioni ormonali (periodo mestruale), alterazioni alimentari (intolleranze a pomodori, cioccolato). Alcuni farmaci inoltre possono essere causa scatenante (acido nifiumico, captopril, diclofenac, fenobarbital, piroxicam, beta bloccanti). Tra i fattori microbiologici prove a sostegno di tale aspetto causale è legato all'isolamento nelle lesioni di adenovirus e virus dell'herpes simplex. However, there is a very common inflammatory condition of the oral mucosa defined as RAU (Recurrent Aphthous Ulcer) which affects 25% of the population albeit episodically and is characterized by extremely painful recurrent, non-contagious single or multiple ulcers. It can present in a mild or severe form. The mild form is the most common and constitutes about 80% of all aphthosis characterized by extremely painful recurrent, non-contagious single or multiple ulcers. The greatest incidence is recorded between 10 and 25 years. In 50% of cases it is possible to find familiarity. It usually presents as a single, oval, painful ulcer with a diameter of less than 10 mm, covered by a fibrinous membrane, surrounded by an erythematous border. Multiple lesions are rarer. Minor aches last about 10-14 days and heal spontaneously without leaving scars. Relapses vary from person to person, disease-free periods vary from weeks to years. The etiopathogenesis is complex and completely unclear. Excluding serious pathologies (in which oral aitosis is a symptom) such as celiac disease, Crohn's disease, ulcerative colitis, (of course, neoplastic lesions of the oral mucosa that can present as ulcers must be excluded) and any iron deficiency, folate and zinc, afiosa stomatitis can indicate a reduction in immune defenses, hormonal alterations (menstrual period), dietary alterations (intolerances to tomatoes, chocolate). Some drugs can also be a trigger (nifiumic acid, captopril, diclofenac, phenobarbital, piroxicam, beta blockers). Among the microbiological factors, evidence supporting this causal aspect is related to the isolation in lesions of adenovirus and herpes simplex virus.
Recentemente sono stati utilizzati per il trattamento e prevenzione della stomatite (post chemio-radioterapia) e delle ulcere della mucosa orale in genere collutori e/o gel a base di: 1) vitamina E; 2) Aloe vera acido glicirretinico+benzalconio cloruro acido ialuronico e gomma xantano: (ALOVEX Recordati, Italy) in forma di collutorio, gel e spray; 3) acido glicirretinico+benzalconio cloruro acido ialuronico, polivinilpirrolidone idrossietilcellulosa in bustine da diluire in 40 mi di acqua d'acqua ed effettuare sciacqui (GELCLAIR Sinclair Pharmaceuticals Limited, UK; 4) acido glcirretinico aloe vera sodio ialuronato polivinilpirrolidone in forma di collutorio (RINCINOL P.R.N. Sunstar Butler). Recently, mouthwashes and / or gels based on: 1) vitamin E have been used for the treatment and prevention of stomatitis (post chemo-radiotherapy) and ulcers of the oral mucosa in general; 2) Aloe vera glycyrrhetinic acid + benzalkonium chloride hyaluronic acid and xanthan gum: (ALOVEX Recordati, Italy) in the form of mouthwash, gel and spray; 3) glycyrrhetinic acid + benzalkonium chloride, hyaluronic acid, polyvinylpyrrolidone hydroxyethylcellulose in sachets to be diluted in 40 ml of water and rinsing (GELCLAIR Sinclair Pharmaceuticals Limited, UK; 4) glcyrretinic acid aloe vera sodium hyaluronate polyvinylpyrrolidone in the form of P.R.N. Sunstar Butler).
Pur essendo soddisfacente l’efficacia dei prodotti attualmente utilizzati in clinica, è sentito il bisogno di un prodotto che possieda delle caratteristiche protettive, antiinfiammatorie, analgesiche ottimali unite a proprietà disinfettanti. While the efficacy of the products currently used in the clinic is satisfactory, the need is felt for a product that possesses optimal protective, anti-inflammatory and analgesic characteristics combined with disinfectant properties.
Sintesi dell’ invenzione Summary of the invention
Si tratta di una composizione ad uso odontoiatrico per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale complicanze comuni della chemioterapia e radioterapia, e conseguenti ad apparecchi dentali mal eseguiti o che si adattano scarsamente alle gengive, ad apparecchi ortodontici traumatizzanti per le mucose orali, allo spazzolamelo troppo energico e/o condotto con spazzolini con setole dure, per fratture di denti e/o otturazioni, morsi ai tessuti interni della bocca, bruciature da cibo, danni dovuti a procedure dentali aggressive, o come conseguenza di igiene orale professionale o sbiancamento professionale, traumi in genere, conseguenti ad una condizione infiammatoria molto comune della mucosa orale definita come RAU (Recurrent Aphthous Ulcer) ed anche lesioni di continuità dopo interventi di chirurgia orale, It is a composition for dental use for the prevention and treatment of stomatitis and ulcerations of the oral mucosa, common complications of chemotherapy and radiotherapy, and consequent to dental appliances poorly made or which adapt poorly to the gums, to traumatizing orthodontic appliances for oral mucous membranes, to brushing it too vigorously and / or conducted with toothbrushes with hard bristles, for fractures of teeth and / or fillings, bites to the internal tissues of the mouth, food burns, damage due to aggressive dental procedures, or as a result of oral hygiene professional or professional whitening, trauma in general, resulting from a very common inflammatory condition of the oral mucosa defined as RAU (Recurrent Aphthous Ulcer) and also continuity lesions after oral surgery,
Tale composizione comprende una soluzione che può essere applicata topicamente tramite spray sulle zone sopracitate o come collutorio attraverso sciacqui del cavo orale, o come gel topico da applicare direttamente sulle lesioni con il beccuccio applicatore del tubo, o con il dito o con un bastoncino cotonato. Nel caso tale composizione sia sotto forma di gel, può essere utilizzata anche come dentifricio mediante spazzolamento; This composition comprises a solution that can be applied topically by spray on the aforementioned areas or as a mouthwash through mouth rinses, or as a topical gel to be applied directly on the lesions with the applicator nozzle of the tube, or with the finger or with a cotton swab. If this composition is in the form of a gel, it can also be used as a toothpaste by brushing;
E’ scopo della presente invenzione fornire una composizione utilizzata nella prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale che abbia ima spiccata capacità nella promozione della guarigione di tali lesioni, in aggiunta a capacità analgesiche, antiinfiammatorie ed antisettiche, oltre che protettive consentendo un’elevata percentuale di risposta, unita alla praticità d’uso. It is an object of the present invention to provide a composition used in the prevention and treatment of stomatitis and ulcerations of the oral mucosa that has a strong ability to promote the healing of such lesions, in addition to analgesic, anti-inflammatory and antiseptic capabilities, as well as protective allowing a high response rate, combined with ease of use.
Questo scopo viene raggiunto dalla composizione secondo l’invenzione, la cui caratteristica è di comprendere la resina di Mirra (Commyphora molmol) come estratto fluido, un disinfettante, un sale solubile di zinco, unitamente all'acido glicirretinico ed a una sostanza mucoadesiva. This purpose is achieved by the composition according to the invention, the characteristic of which is to include Myrrh resin (Commyphora molmol) as a fluid extract, a disinfectant, a soluble zinc salt, together with glycyrrhetinic acid and a mucoadhesive substance.
Preferibilmente il disinfettante scelto è nella famiglia dei disinfettanti cationici, in particolare: il benzalconio cloruro, benzetonio cloruro, clorexidina gluconato, cetrimide, cetilpiridinio cloruro. In preferenza tra i disinfettanti scelto è la clorexidina gluconato. Preferably the disinfectant selected is from the family of cationic disinfectants, in particular: benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, cetrimide, cetylpyridinium chloride. In preference among the disinfectants chosen is chlorhexidine gluconate.
In preferenza i sali solubili di zinco sono scelti tra: The soluble zinc salts are preferably selected from:
cloruro di zinco, citrato di zinco, solfato di zinco, gluconato di zinco, acetato di zinco. In preferenza tra i sali solubili di zinco è scelto il cloruro di zinco. zinc chloride, zinc citrate, zinc sulphate, zinc gluconate, zinc acetate. Preferably zinc chloride is chosen from among the soluble zinc salts.
In preferenza tra le sostanze mucoadesive sono scelte tra: polivinilpirrolidone, polivinilpirrolidone-vinilacetato, chitosano, acido ialuronico, alginato di sodio, etilcellulosa, sucralfato, gomma xantano, idrossipropilmetilcellulosa, carbossimetilcellulosa. In preferenza tra le sostanze mucoadesive è scelto il polivinilpirrolidone vinilacetato per il collutorio ed il dentifricio, l'etilcellulosa per il gel topico. Preferably among the mucoadhesive substances are chosen among: polyvinylpyrrolidone, polyvinylpyrrolidone-vinylacetate, chitosan, hyaluronic acid, sodium alginate, ethylcellulose, sucralfate, xanthan gum, hydroxypropylmethylcellulose, carboxymethylcellulose. Polyvinylpyrrolidone vinyl acetate is preferred among the mucoadhesive substances for the mouthwash and toothpaste, ethylcellulose for the topical gel.
La composizione farmaceutica secondo l’invenzione consente di superare i problemi suddetti legati alle parziali proprietà analgesiche/antiinfiammatorie/disinfettanti nei suddetti prodotti utilizzati nella pratica clinica. L’associazione di un disinfettante cationico insieme ad un sale di zinco, con l'estratto di mirra, unitamente all'acido glicirretinico consente, sorprendentemente la scomparsa della sintomatologia in tempi significativamente inferiori rispetto ai prodotti attualmente utilizzati in clinica, e consente di ottenere delle percentuali di guarigione superiori rispetto ai suddetti prodotti utilizzati in clinica. Tale sorprendente attività è legata ad una azione sinergica dei disinfettanti cationici insieme allo ione zinco (che ha proprietà disinfettanti) con l’attività disinfettante ed analgesica della Mirra ed alla azione antiinfiammatoria dell'acido glicirretinico. The pharmaceutical composition according to the invention allows to overcome the aforementioned problems related to the partial analgesic / anti-inflammatory / disinfectant properties in the aforementioned products used in clinical practice. The association of a cationic disinfectant together with a zinc salt, with the extract of myrrh, together with the glycyrrhetinic acid surprisingly allows the disappearance of the symptoms in significantly shorter times than the products currently used in the clinic, and allows to obtain higher cure rates than the aforementioned products used in the clinic. This surprising activity is linked to a synergistic action of cationic disinfectants together with the zinc ion (which has disinfectant properties) with the disinfectant and analgesic activity of Myrrh and the anti-inflammatory action of glycyrrhetinic acid.
La proporzione ponderale generale per il collutorio è la seguente: Mirra estrato fluido 0,01 -3 g The general weight ratio for the mouthwash is as follows: Myrrh fluid extract 0.01 -3 g
Acido glicirretico 0,01-3g Glycyrrhetic acid 0.01-3g
Clorexidina digluconato 0,01 -0,5g Chlorhexidine digluconate 0.01 -0.5g
Zinco cloruro 0,01-0, 5 g Zinc chloride 0.01-0.5 g
Polivinilpirrolidone-vinilacetato 0, 1 -5g Polyvinylpyrrolidone-vinyl acetate 0, 1 -5g
Aroma menta 0,05-0,5g Mint flavor 0.05-0.5g
Aroma arancio 0,05-1 g Orange flavor 0.05-1 g
Saccarina sodica 0,l-0,5g Sodium saccharin 0, l-0.5g
Colorante verde 0,01-0,05g Green dye 0.01-0.05g
Metile-para-idrossibenzoato 0,01 -0,03 g Methyl para-hydroxybenzoate 0.01-0.03 g
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
La proporzione ponderale generale per il gel topico è la seguente: Mirra estratto fluido 0,01 -3 g The general weight ratio for the topical gel is as follows: Myrrh fluid extract 0.01 -3 g
Acido glicirretico 0,01 -3 g Glycyrrhetic acid 0.01 -3 g
Zinco cloruro 0,01-0, 5g Zinc chloride 0.01-0.5g
Clorexidina digluconato 0,01-0, 5g Chlorhexidine digluconate 0.01-0.5g
Colorante verde 0,01 -0,05 g Green dye 0.01-0.05 g
Idrossietilcellulosa l-5g Hydroxyethylcellulose l-5g
Metile-para-idrossibenzoato 0,01 -0,3g Methyl-para-hydroxybenzoate 0.01 -0.3g
Aroma menta 0,05-0, 5 g Mint flavor 0.05-0.5 g
Aroma arancio 0,05- lg Orange flavor 0.05- lg
Saccarina sodica 0,l-0,5g Sodium saccharin 0, l-0.5g
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
La proporzione ponderale generale per il gel dentifricio è la seguente: Mirra estrato fluido 0,01 -3g The general weight ratio for the toothpaste gel is as follows: Myrrh fluid extract 0.01 -3g
Acido glicirretico 0,01 -3 g Glycyrrhetic acid 0.01 -3 g
Zinco cloruro 0,01-0, 5g Zinc chloride 0.01-0.5g
Clorexidina digluconato 0,01-0, Sg Chlorhexidine digluconate 0.01-0, Sg
Sacccarina sodica 0,05-0,5g Sodium sacccarina 0.05-0.5g
Colorante verde 0,01-0,05 g Green dye 0.01-0.05 g
Glicerina 30-60g Glycerin 30-60g
Silice micronizzata 5-30g Micronized silica 5-30g
Aroma menta 0,05-0,5g Mint flavor 0.05-0.5g
Aroma arancio 0,05- lg Orange flavor 0.05- lg
Sodio lauril solfato l-4g Sodium lauryl sulfate l-4g
Polivinilpirrolidone vinilacetato 0,5-3g Polyvinylpyrrolidone vinyl acetate 0.5-3g
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
L'uso della resina di Mirra (Commyphora molmol) (che ha capacità analgesiche e disinfettanti) di un disinfettante cationico più un sale solubile di zinco (che ha azione disinfettante ed antivirale) unita con l'acido glicirretinico (che ha azione antiinfiammatoria), non è noto nella tecnica del settore odontoiatrico, dove invece è ottimamente utilizzabile secondo la presente invenzione. The use of Myrrh resin (Commyphora molmol) (which has analgesic and disinfectant capacities) of a cationic disinfectant plus a soluble zinc salt (which has disinfectant and antiviral action) combined with glycyrrhetinic acid (which has anti-inflammatory action), it is not known in the technique of the dental sector, where instead it can be optimally used according to the present invention.
Allo scopo di illustrare meglio la composizione secondo la presente invenzione, si riporta qui di seguito esempi di composizione. In order to better illustrate the composition according to the present invention, examples of composition are given below.
ESEMPIO 1 EXAMPLE 1
Una composizione per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale che utilizza l'uso di un collutorio a base di estratto fluido di resina di Mirra, clorexidina gluconato e cloruro di zinco unitamente ad acido glicirretico, con le seguenti proporzioni ponderali: A composition for the prevention and treatment of stomatitis and ulcerations of the oral mucosa that uses a mouthwash based on a fluid extract of myrrh resin, chlorhexidine gluconate and zinc chloride together with glycyrrhetic acid, with the following weight proportions :
Mirra estratto fluido 0,2 mi Myrrh fluid extract 0.2 ml
Acido glicirretico 0,2g Glycyrrhetic acid 0.2g
Clorexidina digluconato 0,2g Chlorhexidine digluconate 0.2g
Zinco cloruro 0,lg Zinc chloride 0, lg
Polivinilpirrolidone-vinilacetato 1 g Polyvinylpyrrolidone-vinyl acetate 1 g
Aroma menta forte 0,3g Strong mint flavor 0.3g
Aroma arancio 0,4g Orange flavor 0.4g
Saccarina sodica 0,2g Sodium saccharin 0.2g
Colorante verde 0,02g Green dye 0.02g
Metile-para-idrossibenzoato 0,02g Methyl-para-hydroxybenzoate 0.02g
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
E’ utilizzata nel modo seguente per i per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale: It is used in the following way for the prevention and treatment of stomatitis and ulcerations of the oral mucosa:
Effettuare imo sciacquo per circa 2-3 minuti con 10 mi di soluzione, (utilizzando un misurino). L’applicazione va ripetuta tre volte al giorno, o secondo le indicazioni dell 'odontoiatra. Si consiglia dopo l’utilizzo del collutorio di non risciacquare la bocca e di non assumere cibi o bevande per almeno un ora. Rinse for about 2-3 minutes with 10 ml of solution (using a measuring cup). The application should be repeated three times a day, or according to the dentist's instructions. After using the mouthwash, it is recommended not to rinse your mouth and not to eat or drink for at least an hour.
ESEMPIO 2 EXAMPLE 2
Una composizione per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale che utilizza l’uso di un gel topico a base di estratto fluido di resina di Mirra, clorexidina gluconato e cloruro di zinco unitamente ad acido glicirretico, con le seguenti proporzioni ponderali: A composition for the prevention and treatment of stomatitis and ulcerations of the oral mucosa that uses a topical gel based on a fluid extract of myrrh resin, chlorhexidine gluconate and zinc chloride together with glycyrrhetic acid, with the following proportions weight them:
Mirra estratto fluido 0,2 mi Myrrh fluid extract 0.2 ml
Acido glicirretico 0,2g Glycyrrhetic acid 0.2g
Zinco cloruro 0,2g Zinc chloride 0.2g
Clorexidina digluconato 0,2g Chlorhexidine digluconate 0.2g
Colorante verde 0,02g Green dye 0.02g
Idrossietilcellulosa 3,25g Hydroxyethylcellulose 3.25g
Metile-para-idrossibenzoato 0,lg Methyl para-hydroxybenzoate 0, lg
Aroma menta 0,3g Mint flavor 0.3g
Aroma arancio 0,5g Orange flavor 0.5g
Saccarina sodica 0,3g Sodium saccharin 0.3g
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
Tale composizione viene utilizzata nel modo seguente per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale: This composition is used in the following way for the prevention and treatment of stomatitis and ulcerations of the oral mucosa:
si applica il gel sulla zona desiderata direttamente con il beccuccio del tubo, tramite un dito o con un bastonicino cotonato. Applicare il gel ogni 4-6 ore, o secondo le indicazioni dell'odontoiatra. Non assumere cibi o bevande per almeno un ora dopo l'applicazione del gel. the gel is applied to the desired area directly with the nozzle of the tube, with a finger or with a cotton swab. Apply the gel every 4-6 hours, or as directed by the dentist. Do not take food or drink for at least one hour after applying the gel.
ESEMPIO 3 EXAMPLE 3
Una composizione per la prevenzione ed il trattamento della stomatite e delle ulcerazioni della mucosa orale che utilizza l’uso di un gel dentifricio a base di estratto fluido di resina di Mirra, clorexidina gluconato e cloruro di zinco unitamente ad acido glicirretico, con le seguenti proporzioni ponderali: A composition for the prevention and treatment of stomatitis and ulcerations of the oral mucosa that uses a toothpaste gel based on fluid extract of myrrh resin, chlorhexidine gluconate and zinc chloride together with glycyrrhetic acid, with the following proportions weight them:
Mirra estrato fluido 3ml Myrrh fluid extract 3ml
Acido glicirretico 0,3 g Glycyrrhetic acid 0.3 g
Zinco cloruro 0,2g Zinc chloride 0.2g
Clorexidina digluconato 0,2g Chlorhexidine digluconate 0.2g
Sacccarina sodica 0,25g Sodium sacccarina 0.25g
Colorante verde 0,03g Green dye 0.03g
Glicerina 60g Glycerin 60g
Silice micronizzata 15g Micronized silica 15g
Aroma menta 0,3g Mint flavor 0.3g
Aroma arancio 0,5g Orange flavor 0.5g
Sodio lauril solfato 2g Sodium lauryl sulfate 2g
Polivinilpirrolidone vinilacetato lg Polyvinylpyrrolidone vinyl acetate lg
Acqua depurata q.b. a lOOg Purified water q.s. to lOOg
Tale composizione viene utilizzata nel modo seguente per la prevenzione ed il tratamento della stomatite e delle ulcerazioni della mucosa orale: This composition is used in the following way for the prevention and treatment of stomatitis and ulcerations of the oral mucosa:
si applica sul uno spazzolino morbido una quantità desiderata di gel dentifricio, quindi si strofina delicatamente entrambe le arcate dentarie con movimento dall’alto in basso per circa due minuti. a desired amount of toothpaste gel is applied to a soft toothbrush, then gently rubs both dental arches with movement from top to bottom for about two minutes.
Si deve insistere maggiormente con lo spazzolamento su quelle regioni dentarie che risultano vicine alle zone di mucosa interessate dai processi infiammatori/ulcerativi. It is necessary to insist more with brushing on those dental regions that are close to the mucosal areas affected by inflammatory / ulcerative processes.
Quindi si risciacqua il cavo orale con abbondante acqua. Tale procedura deve essere ripetuta tre volte al giorno (dopo i pasti). Non si deve assumere cibi o bevande per almeno un ora dopo l'uso del gel dentifricio. Then rinse the mouth with plenty of water. This procedure must be repeated three times a day (after meals). You should not take any food or drink for at least one hour after using the toothpaste gel.
Varianti e/o modifiche potranno essere apportate alla composizione secondo la presente invenzione senza per questo uscire dall’ ambito protettivo dell’invenzione medesima. Variations and / or modifications may be made to the composition according to the present invention without thereby departing from the protective scope of the invention itself.
Claims (4)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000035A ITFI20080035A1 (en) | 2008-02-26 | 2008-02-26 | DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA |
PCT/IB2009/000359 WO2009106963A2 (en) | 2008-02-26 | 2009-02-26 | Dental composition for preventing and treating stomatitis and mouth ulcers |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000035A ITFI20080035A1 (en) | 2008-02-26 | 2008-02-26 | DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA |
Publications (1)
Publication Number | Publication Date |
---|---|
ITFI20080035A1 true ITFI20080035A1 (en) | 2009-08-27 |
Family
ID=40291538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IT000035A ITFI20080035A1 (en) | 2008-02-26 | 2008-02-26 | DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA |
Country Status (2)
Country | Link |
---|---|
IT (1) | ITFI20080035A1 (en) |
WO (1) | WO2009106963A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1398050B1 (en) * | 2010-02-02 | 2013-02-07 | Lastri | COMPOSITION FOR ORAL HYGIENE CONTAINING CLOREXIDINE AND A SYSTEM TO PREVENT THE FORMATION OF DARK PIGMENTS ON THE SURFACE OF TEETH AND ORAL MUCOS |
CN103908458A (en) * | 2013-01-04 | 2014-07-09 | 厦门鹭佳生物科技有限公司 | Application of glycyrrhetinic acid and glycyrrhizic acid in preparation of medicines for preventing or treating radioactive soft tissue injury |
JP6300828B2 (en) * | 2013-02-07 | 2018-03-28 | ゴンザレス トマス ベルナルド ガルヴァン | Oral bactericidal composition for treating oral mucositis |
EP2896396A1 (en) | 2014-01-20 | 2015-07-22 | Abem Kimya Tibbi Malzemeler Yönetim Danismanligi Temizlik Servis Hizmetleri Sanayi Ve Dis Ticaret Limited Sirketi | Herbal formulation for topical wound treatment |
CN103893613B (en) * | 2014-04-25 | 2016-08-24 | 常桂欣 | A kind of medicine treating oral ulcer and preparation method |
NO342617B1 (en) * | 2014-06-18 | 2018-06-18 | Meda Otc Ab | Oral formulation comprising an antibacterial agent to prevent and / or treat halitosis, bad breath, dry mouth or sore throat |
CN104367503A (en) * | 2014-10-29 | 2015-02-25 | 姜专基 | Special tumor chemotherapy toothpaste and preparation method thereof |
WO2016126217A1 (en) * | 2015-02-03 | 2016-08-11 | Pharmacti̇ve Ilaç Sanayi̇ Ve Ti̇caret A. Ş. | Stable pharmaceutical combination containing benzydamine |
RU2607931C2 (en) * | 2015-04-23 | 2017-01-11 | Елена Ароновна Картон | Therapeutic composition for oral care for hematology-oncology patients |
CN104800283A (en) * | 2015-04-29 | 2015-07-29 | 广州玖玖伍捌健康科技股份有限公司 | Tooth flushing fluid and preparation method thereof |
BR112016019932B1 (en) * | 2015-05-08 | 2020-12-01 | Curasept Ads S.R.L | antipigmentation system for a mouthwash, mouthwash, method for the prevention and cosmetic and therapeutic treatment of plaque and gingivitis, method for preventing stains on the surface of teeth and uses of mouthwash |
CN105148093A (en) * | 2015-10-21 | 2015-12-16 | 罗盈 | Tablet for treating dental ulcer |
DE202016100357U1 (en) * | 2016-01-27 | 2016-03-09 | Peter Sommer | Pharmaceutical preparation and use thereof in viral inflammatory diseases of the upper respiratory tract |
KR102619680B1 (en) * | 2016-07-22 | 2024-01-02 | 애경산업(주) | Oral composition for inhibiting the halitosis |
US11331360B2 (en) | 2018-10-05 | 2022-05-17 | Umayana Llc | Commiphora molmol (myrrh) resin extracts and uses thereof for wound healing and treatment and prevention of mucositis and other diseases |
IT201900000391A1 (en) * | 2019-01-10 | 2020-07-10 | L N Age S R L | COMPOSITION FOR USE IN THE TREATMENT OF SKIN INJURIES IN CANCER PATIENTS |
IT202000016639A1 (en) * | 2020-07-09 | 2022-01-09 | Daniele Scetta | COMPOSITION FOR USE IN THE TREATMENT OF ESOPHAGEAL BURNING AND/OR PAIN ASSOCIATED WITH GASTROESOPHAGEAL REFLUX DISORDER OR DISEASE. |
EP4331561A1 (en) * | 2022-08-31 | 2024-03-06 | Unilever IP Holdings B.V. | Use of oral care composition |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6231836B1 (en) * | 1999-07-12 | 2001-05-15 | Robert Takhtalian | Folic acid dentifrice |
DE10026716A1 (en) * | 2000-05-30 | 2001-12-13 | Ferton Holding Sa | Prophylactic mouthwash solution, especially for use together with an abrasive powder, comprises an antimicrobial or bacteriostatic and tooth-remineralizing agent |
EP1685875A1 (en) * | 2005-01-28 | 2006-08-02 | Gumlink A/S | Multi functional oral care chewing gum |
DE202006005924U1 (en) * | 2006-04-10 | 2007-05-16 | Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh | Pharmaceutical composition, useful for prophylactic and/or curative topical treatment for rhinitis, in the form of liquid formulation for intranasal application, comprises sodium chloride and myrrh |
-
2008
- 2008-02-26 IT IT000035A patent/ITFI20080035A1/en unknown
-
2009
- 2009-02-26 WO PCT/IB2009/000359 patent/WO2009106963A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2009106963A3 (en) | 2010-05-27 |
WO2009106963A2 (en) | 2009-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ITFI20080035A1 (en) | DENTAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF STOMATITIS AND ULCERAZONIES OF ORAL MUCOSA | |
JP2927850B2 (en) | Topical preparations for the treatment of symptoms of teeth and their supporting tissues | |
ES2394344T5 (en) | Use of bovine lactoferrin to treat destructive inflammation of a mucous membrane | |
ATE323498T1 (en) | OLIGOSACCHARIDEALDONIC ACID AND ITS TOPICAL ADMINISTRATION | |
ES2885449T3 (en) | Oral antiseptic composition for the treatment of oral mucositis | |
ES2314304T3 (en) | TOPIC PHARMACEUTICAL COMPOSITIONS CONTAINING PROPER NATURAL ACTIVE PRINCIPLES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY PROCESSES OF MUCOSES. | |
CN104398396A (en) | Compositions and methods for the treatment of xerostomia | |
US9895326B2 (en) | Topical oral composition for alleviating dry mouth symptoms and for treating mouth ulcers | |
RU2012149868A (en) | SEED POLYSACCHARIDE FOR APPLICATION IN TREATMENT OF INFLAMMATORY DISEASES | |
RU2550957C1 (en) | Method of treating chronic generalised periodontitis | |
Steinberg et al. | Dental drug-delivery devices: local and sustained-release applications | |
Ilango et al. | Chlorhexidine: a miracle chemical | |
ITMI971091A1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING COLOSTRUM AND USE OF COLOSTRUM FOR THE TREATMENT OF ORAL CAVITY DISEASES | |
Van Zyl et al. | Mouthwash: a review for South African health care workers: CPD | |
US20190321308A1 (en) | Compositions containing tetrahydrocurcuminoids for improvement of oral health and hygiene | |
RU2813879C1 (en) | Anti-inflammatory composition (versions) for local application in oral cavity and upper respiratory tract | |
JPH0761933B2 (en) | Oral composition | |
Chirkova et al. | Complex treatment of patients with chronic generalized catarrhal gingivitis: probiotic review study | |
Abed et al. | Comparison between the effects of Aloe vera and chlorhexidine on clinical periodontal parameters | |
Schmidt | Mouthwashes and gargles: oral health | |
Van Schoor | Using gargles and mouthwashes: Medicine cupboard | |
RU2296559C2 (en) | Healthy agent for oral cavity care (variants) | |
JPH0637379B2 (en) | Topical for treatment of periodontal disease | |
JPS63500657A (en) | Composition for manufacturing a drug for local treatment of periodontal tissue diseases | |
JP2001294536A (en) | Prophylactic/therapeutic preparation for periodontal disease |